Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers

Martina Amato 1, Renato Franco 1,*, Gaetano Facchini 2, Raffaele Addeo 3, Fortunato Ciardiello 4, Massimiliano Berretta 5, Giulia Vita 6, Alessandro Sgambato 7, Sandro Pignata 8, Michele Caraglia 9, Marina Accardo 1,† and Federica Zito Marino 1,†

1 Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, Italy
2 Medical Oncology Unit, SM delle Grazie Hospital, 80078 Pozzuoli, Italy
3 Medical Oncology Unit, San Giovanni di Dio Hospital, 80027 Frattamaggiore, Italy
4 Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, 80131 Naples, Italy
5 Department of Clinical and Experimental Medicine, University of Messina, 98121 Messina, Italy
6 Anatomical Pathology Department, IRCCS CROB, 85028 Rionero in Vulture, Italy
7 Scientific Direction, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Rionero in Vulture, Italy
8 Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, IRCCS, 80131 Naples, Italy
9 Department of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, Italy
* Correspondence: renato.franco@unicampania.it; Tel.: +39-0815664000
† These authors contributed equally to this work.

Abstract: Microsatellite instability (MSI) has been identified in several tumors arising from either germline or somatic aberration. The presence of MSI in cancer predicts the sensitivity to immune checkpoint inhibitors (ICIs), particularly PD1/PD-L1 inhibitors. To date, the predictive role of MSI is currently used in the selection of colorectal cancer patients for immunotherapy; moreover, the expansion of clinical trials into other cancer types may elucidate the predictive value of MSI for non-colorectal tumors. In clinical practice, several assays are used for MSI testing, including immunohistochemistry (IHC), polymerase chain reaction (PCR) and next-generation sequencing (NGS). In this review, we provide an overview of MSI in various cancer types, highlighting its potential predictive/prognostic role and the clinical trials performed. Finally, we focus on the comparison data between the different assays used to detect MSI in clinical practice.

Keywords: microsatellite instability; mismatch repair; immunotherapy; immunohistochemistry; PCR; NGS

1. Introduction

Microsatellites (MSs) are repeated sequences of 1–6 nucleotides in the human genome. MSs are highly polymorphic; in particular, their distribution and their dimensions are variable [1,2]. MSs are widely used both as markers in studies of genetic disease and as predictive biomarkers in various cancer types [3–5]. MSs are often subject to the incorporation or deletion of repeated units made by DNA polymerase during DNA replication; the mismatch repair system (MMR) is generally able to correct these errors [6]. The MMR is a pivotal system for maintaining genome integrity, consisting of several proteins, such as MLH1, MLH3, MSH2, MSH6, MSH3, PMS2, PMS1 and Exo1. The DNA errors are detected by MSH2/MSH6 and MSH2/MSH3 heterodimers; subsequently, the MLH1/PMS2 complex nicks DNA at sites of mismatch in order to begin strand repair [7]. MLH1 and MSH2 are the primary partners of their heterodimer, while PMS2 and MSH6 are the respective secondary partners. Consequently, the loss of the primary partners results in the loss of the entire
heterodimer, but not the opposite. The alteration of the MMR proteins leads to a biological status known as microsatellite instability (MSI) [8]. The generation of MSI can be caused by the point mutations occurring in MMR genes, the DNA polymerase slippage during the replication process and the insertion/deletion of one or more bases in the microsatellite regions [1]. Furthermore, the MSI status could be due to other aberrations, including the hypermethylation of the MLH1 promoter [9], the epigenetic inactivation of MSH2 or MLH1 [10,11], the downregulation of MMR genes by microRNAs [12] or the slipped strand mating error (SSM) [13]. The MSI phenotype could be related to Lynch syndrome (LS), a genetic disease characterized by inherited germline mutations in MMR genes that is mainly shown in colorectal cancer and endometrial cancer; however, it is also shown in ovarian cancer, gastric cancer, the hepatobiliary tract, upper urinary tract, pancreas, brain and skin [14–17]. The presence of MSs in the coding regions is prone to generate genetic instability, leading to carcinogenesis [18]. Oda et al. proposed MSI classification into type A, with a variation of <6 bp, and type B, with a variation of >8 bp. Thibodeau et al. classified MSI based on the increase or decrease in fragment size into type I and II, respectively [19,20]. MSI was identified for the first time in colorectal cancer (CRC) [21]; subsequently, it was reported in endometrial cancer, ovarian cancer and gastric cancer (Figure 1). In recent years, MSI has also been identified with less frequency in other tumors, such as non-small cell lung cancer, breast cancer, brain cancer, prostate cancer, pancreatic cancer, bladder cancer and melanoma [22–26]. The immune checkpoint inhibitors (ICI) have been shown to be effective in several tumor types carrying MSI-H compared to chemotherapy [27–29]. The rationale behind the sensitivity to ICI of MSI-H tumors is probably due to the accumulation of mutations that determines new mutated peptides, leading to the activation of the immune system [30]. In this context, MSI tumors have a high level of T-helper 1/cytotoxic lymphocytes and immune checkpoint molecules such as CTLA4, PD-1, PD-L1, LAG-3 and IDO, compared to MSS tumors [31,32]. The tumors carrying MSI showed a much better response to ICI than MSS cancers [33]. In recent years, the immunotherapy has achieved excellent results in several cancer types with the MSI phenotype [34]. In 2017, the US Food and Drug Administration (FDA) approved pembrolizumab, a PD-1 inhibitor, for the treatment of MSI advanced solid tumors regardless of the cancer type and the histology. MSI is the first cancer type-agnostic biomarker approved to establish the eligibility of patients for treatment with ICI rather than the site of the tumor [27].

Figure 1. Frequency of microsatellite instability in gastrointestinal and gynecologic cancers. Distribution of MSI according to the molecular classification of colorectal cancer, gastric cancer, ovarian and endometrial...
cancers. CIN: chromosome instability; CIMP: CpG island methylator phenotype; MSI: microsatellite instability; EBV: Epstein–Barr virus; GS: genomically stable; NSMP: no specific molecular profile; POLE: DNA polymerase epsilon.

2. Methods of MSI Detection

The MSI implication in cancer leads researchers to develop several techniques for its detection. The MSI phenotype could be defined both by a molecular approach evaluating the microsatellite sequences and by IHC evaluating the expression of MMR proteins (MMRP). The immunohistochemistry (IHC) analyzes the expression of a limited number of MMR proteins, including MLH1, PMS2, MSH2 and MSH6. MLH1 and MSH2 are the primary partners, and their degradation leads to the loss of their respective partners [35]. The proficient MMR (pMMR) cases show positive staining of the nuclei of all four MMRP; the deficient MMR (dMMR) cases show the loss of one of the two MLH1/PMS2 or MSH2/MSH6 heterodimers; the patchy MMR cases show focal IHC staining or cytoplasmic staining of one or more MMRP [36,37]. Some studies suggest that IHC could be exclusively used as a screening method for MSI detection since it is fast, easy to perform, inexpensive and widespread to most pathological laboratories [38–41]. Previous findings showed that both technical and interpretative pitfalls affect the MMR IHC, leading to false IHC results [42]. MSI-PCR is currently performed through two commercial panels, the Bethesda and the Pentaplex. The Bethesda panel includes five predefined genomic regions: two single-nucleotide (BAT25, BAT-26) and three dinucleotides (D2S123, D5S346 and D17S250). The Pentaplex panel includes five single-nucleotide loci, including BAT-25, BAT-26, NR-21, NR-24 and NR-27 [46,47]. The microsatellite status can be classified according to the number of instability markers, as follows: (i) high microsatellite instability (MSI-H) when there are more than 2 unstable loci; (ii) low microsatellite instability (MSI-L) when there is only one unstable locus; and (iii) microsatellite stability (MSS) when all the microsatellites are stable [48]. MSI-L and MSS tumors have similar molecular and clinical features; thus, patients carrying MSI-L are classified as MSS and they are not sensitive to ICI compared to patients carrying MSI-H [1]. MSI-PCR is a highly sensitive technique that is able to identify the instability due to the non-truncating mutations generally associated with a false positive IHC staining [41].

To date, both IHC and PCR are used in the clinical practice of MSI testing to define patients who can benefit from ICI treatment. However, several data in the literature showed discordant results between IHC and PCR in MSI detection. Several studies demonstrated that MMR IHC results frequently have not been confirmed by molecular analysis. For example, some cases of dMMR-IHC are results of MSS by PCR, resulting in clinical implications in the therapeutic choice. Likewise, cases with pMMPR-IHC were unexpectedly MSI by PCR [41,49–52]. These controversial results are generally attributable to the technical limits related to MMR IHC or a misinterpretation of the staining [41].

Recently, the next-generation sequencing (NGS) is another method used for MSI detection [2,53]. Several NGS-based methods have been described to assess MSI, including MSIseq somatic mutation analysis [54], mSINGS [53], MSISensor [55], Microsatellite Analysis for Normal Tumor Instability (MANTIS) [56], ColoSeq [57] and MSI-ColonCore [58]. The main advantage of an NGS-based approach is the simultaneous screening of microsatellite loci and other mutations including TMB [59].
In conclusion, tumors with the loss or equivocal staining of at least one of the MMRP by IHC require an additional molecular test in order to avoid misdiagnosis and consequently inappropriate treatment choices [60] (Figure 2).

Figure 2. The diagnostic algorithm of MSI status. MMRP IHC is used as a screening test: the intact expression of all four MMRPs is a conclusive result of the MSS status (original magnification 10×); the heterogeneous staining of one or more MMRPs needs an additional molecular assay (original magnification 10×); and the loss of one or more MMRPs needs a molecular assay (original magnification 10×). The molecular analysis performed through PCR and/or NGS leads to a conclusive result in cases with IHC equivocal staining. MMRP: mismatch repair proteins; IHC: immunohistochemistry; PCR: polymerase chain reaction; NGS: new-generation sequencing; MSS: microsatellite stability; MSI-L: microsatellite instability-low; MSI-H: microsatellite instability-high. The stars indicate the PMS2 heterogeneous staining (center) and the loss of MLH1 and PMS2 (right).

3. MSI in Colorectal Cancer

The Cancer Genome Atlas Network (TCGA) has included the MSI status in the molecular classification of CRC. Particularly, the TCGA classified CRC in different molecular subsets, including the chromosome instability phenotypes (CIN), accounting for 70% of cases, the MSI phenotype, accounting for 20%, and the CpG island methylation phenotype (CIMP), accounting for 10% [61] (Figure 1). Although some studies showed that some MSI CRC cases harbouring also CIMP and CIN overlap with different molecular phenotypes, TCGA classified MSI CRC as a distinct molecular phenotype [62,63]. Approximately 3% to 5% of all CRCs have dMMR associated with LS. This syndrome, known as hereditary non-polyposis colorectal carcinoma (HNPCC), is an autosomal dominant syndrome with germline mutations of the MMR genes [64–66]. Beyond the CRCs associated with LS, approximately 70–95% of MSI CRCs are sporadic [67]. The relationship between CRC MSI and some clinical features, such as primary right-sided tumors and older age, has been demonstrated [68]. The MSI status is an early event in the development of CRC; it has never been identified in polyps [69]. On the contrary, MSI has also been observed in the normal colonic mucosa of patients with LS [70–72]. Several studies suggest that MSI CRCs
at advanced stages show a poor prognosis compared to MSS CRC [73,74]. The clinical studies KEYNOTE-016 and KEYNOTE-164 demonstrated the efficacy of pembrolizumab, with durable responses in patients with advanced MSI-H/dMMR or mCRC treated after chemotherapy [75,76]. In KEYNOTE-177, a phase 3 study, patients with unresectable or metastatic MSI/dMMR CRC were treated with pembrolizumab as the first-line treatment without receiving prior therapy; this showed clinically significant improvements in survival compared to chemotherapy. In 2020, the FDA approved pembrolizumab as the first-line treatment for advanced or metastatic CRC with MSI-H/dMMR [77]. Furthermore, CheckMate 142 demonstrated the efficacy of nivolumab (an anti-PD1 antibody) used alone or in combination with ipilimumab (an anti-CTLA-4 antibody) in mCRC MSI-H/dMMR patients previously treated with chemotherapy. In 2018, the FDA approved nivolumab either alone or in combination with ipilimumab [78,79] (Table 1). The predictive value of MSI in CRC requires the optimization of testing in clinical practice. As already mentioned, IHC is the most used method; however, it showed several discrepancies with PCR and NGS results. Several studies have compared the different assays for MSI detection in CRC series [41,50,80–82] (Table 2). The comparative analysis between different methods showed several discrepancies; in particular, some of the dMMR-IHC cases were MSS-PCR (ranging from 1% to 33% of cases) [82–84]. In contrast, only 5% of pMMR-IHC cases analyzed in the literature showed MSI by PCR [41,50,81,85]. Generally, the PCR results are in agreement with the NGS results, showing a discrepancy of up to 3% [58,83,86,87]. To date, no recommendations have been proposed regarding the gold standard molecular test for MSI analysis. The NGS is the most sensitive method for MSI detection. Moreover, the NGS represents the best molecular approach since it allows simultaneously the detection of both MSI and a wide panel of other mutations. However, PCR can represent a valid molecular test for MSI detection in daily clinical practice since it is economical and widespread in the laboratories compared to NGS. Finally, MSI analysis by NGS could be useful in selected cases showing discordant results between IHC and PCR.

Table 1. Clinical trials for immune checkpoint inhibitors treatment of MSI CRC.

| Clinical Trial   | Drug Treatment | Phase | Tumor Type                          | N. Patients | Status         | Conclusion                           |
|------------------|----------------|-------|-------------------------------------|-------------|----------------|--------------------------------------|
| NCT02460198      | Pembrolizumab  | 2     | Advanced unresectable CRC           | 124         | Completed      | Pembrolizumab is effective in MSI-H/dMMR CRC |
| KEYNOTE-164      |                |       | mCRC Stage IV                       |             |                |                                      |
| NCT01876511      | Pembrolizumab  | 2     | MSI-H CRC                          | 113         | Completed      | ORR: disappearance of all target lesions PR: 30% decrease in the diameters of the target lesions |
| KEYNOTE-016      |                |       | MSS CRC                            |             |                |                                      |
|                  |                |       | MSI non-CRC                        |             |                |                                      |
| NCT00912743      | Olaparib       | 2     | CRC MSI-H                          | 33          | Completed      | Olaparib activity not demonstrated after failure of standard systemic therapy |
| NCT03374254      | Pembrolizumab  | 1     | mCRC MSS/pMMR                      | 220         | Active, not recruiting | No results posted |
| KEYNOTE-651      | Binimetinib    |       |                                      |             |                |                                      |
|                  | Pembrolizumab  |       | Chemotherapy with or without Binimetinib |             |                |                                      |
| NCT02060188      | Nivolumab alone vs. Nivolumab + Ipilimumab or Nivolumab + BMS-986016 or Nivolumab + Daratumumab | 2 | mCRC MSI-H CRC non-MSI-H | 385 | Active, not recruiting | No results posted |
| CheckMate 142    |                |       |                                      |             |                |                                      |
| NCT04258111      | IBI310 (anti-CTLA-4 antibody) + Sintilimab (anti-PD-1 antibody) | 2 | CRC MSI-H mCRC MSI-H | 4 | Active, not recruiting | No results posted |
| Clinical Trial     | Drug Treatment                                                                 | Phase | Tumor Type                  | N. Patients | Status             | Conclusion                  |
|-------------------|--------------------------------------------------------------------------------|-------|-----------------------------|-------------|--------------------|-----------------------------|
| NCT03435107       | Durvalumab                                                                      | 2     | mCRC MSI-H or POLE          | 33          | Active, not        | No results posted           |
| NCT03350126       | Ipilimumab + Nivolumab                                                          | 2     | mCRC MSI/dMMR               | 57          | Active, not        | No results posted           |
| NCT03186326       | FOLFOX or FOLFIRI Protocol + Panitumumab + Avelumab                             | 2     | mCRC MSI-H                  | 132         | Active, not        | No results posted           |
| NCT02563002       | Pembrolizumab vs. standard therapy (mFOLFOX6 and FOLFIRI alone or associated with Bevacizumab + Cetuximab) | 3     | MSI CRC stage IV            | 307         | Active, not        | Pembrolizumab prolongs PFS or OS |
| NCT03926338       | Toripalimab + Celecoxib vs. Toripalimab alone                                  | 1–2   | MSI-H/dMMR CRC              | 34          | Recruiting         | No results posted           |
| NCT04636008       | Sintilimab + Hypofractionated radiotherapy                                      | 1–2   | Rectal cancer MSI-H/dMMR CRC| 20          | Recruiting         | No results posted           |
| NCT04014530       | Ataluren + Pembrolizumab                                                        | 1–2   | mCRC pMMR and dMMR mEc dMMR | 47          | Recruiting         | No results posted           |
| NCT04988191       | Toripalimab + Bevacizumab + Irinotecan                                         | 1–2   | CRC dMMR/MSI-H              | 44          | Recruiting         | No results posted           |
| NCT04715633       | Camrelizumab + Apatinib                                                        | 2     | Locally advanced dMMR/MSI-H CRC| 52          | Recruiting         | No results posted           |
| NCT03519412       | Temozolomide (induction) Pembrolizumab (treatment)                              | 2     | mCRC pMMR and dMMR         | 102         | Recruiting         | No results posted           |
| NCT05116085       | Tislelizumab                                                                    | 2     | With early-stage (Stage II-III) MSI-H or dMMR CRC| 38          | Recruiting         | No results posted           |
| NCT04715633       | Camrelizumab + Apatinib                                                        | 2     | MSI-H/dMMR CRC              | 52          | Recruiting         | No results posted           |
| NCT05118724       | Atezolizumab                                                                    | 2     | CRC MSI-H/dMMR Stage III    | 120         | Recruiting         | No results posted           |
| NCT04695470       | Fruquintinib + Sintilimab                                                       | 2     | mCRC TMB and non MSI-H      | 70          | Recruiting         | No results posted           |
| NCT03638297       | BAT1306 + Aspirin                                                               | 2     | CRC MSI-H/dMMR or TMB       | 27          | Recruiting         | No results posted           |
| NCT04730544       | Nivolumab + Ipilimumab                                                          | 2     | mCRC dMMR/MSI-H             | 96          | Recruiting         | No results posted           |
| NCT04895722       | Pembrolizumab alone vs. Pembrolizumab + Quavonimab vs. Pembrolizumab + Favezelimab vs. Pembrolizumab + Vibostolimab | 2     | CRC MSI Stage IV            | 320         | Recruiting         | No results posted           |
| NCT04301557       | PD-1 Antibody + Oxaliplatin + Capecitabine + External beam radiotherapy + Total mesorectal excision | 2     | Advanced CRC dMMR/MSI-H     | 25          | Recruiting         | No results posted           |
| Clinical Trial | Drug Treatment | Phase | Tumor Type | N. Patients | Status   | Conclusion         |
|---------------|----------------|-------|------------|-------------|----------|--------------------|
| NCT04304209   | Oxaliplatin + Capecitabine + Sintilimab + Total mesorectal excision vs. Oxaliplatin + Capecitabine + Sintilimab + Radiotherapy + Total mesorectal excision | 2-3   | CRC Stage IICRC Stage III dMMR/MSI-H | 195         | Recruiting         | No results posted  |
| NCT02912559   | Atezolizumab + Fluorouracil vs. Leucovorin calcium + Oxaliplatin vs. Fluorouracil + Leucovorin calcium + Oxaliplatin | 3     | CRC dMMR Stage III | 700         | Recruiting         | No results posted  |
| NCT05239741   | Pembrolizumab alone vs. 5-fluorouracil + Cetuximab or FOLFIRI + Bevacizumab or FOLFIRI + Cetuximab | 3     | CRC MSI-H Stage IV dMMR CRC | 100         | Recruiting         | No results posted  |
| NCT02997228   | Atezolizumab alone vs. mFOLFOX6 + Bevacizumab vs. mFOLFOX6 + Bevacizumab + Atezolizumab | 3     | mCRC MSI-H | 231         | Recruiting         | No results posted  |
| NCT0408030    | Nivolumab alone vs. Nivolumab + Ipilimumab vs. Active comparator (Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab) | 3     | mCRC MSI-H | 748         | Recruiting         | No results posted  |
| NCT05236972   | Sintilimab alone vs. Oxaliplatin + Capecitabine | 3     | CRC dMMR/MSI-H Stage III | 323         | Recruiting         | No results posted  |
| NCT05239741   | Pembrolizumab alone vs. Active comparator (Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab) | 3     | CRC MSI-H/dMMR Stage IV | 100         | Recruiting         | No results posted  |
| NCT05217446   | Pembrolizumab alone vs. Encorafenib + Cetuximab + Pembrolizumab | 2     | mCRC MSI-H/dMMR | 104         | Not yet recruiting | No results posted  |
| NCT05217446   | Pembrolizumab alone vs. Encorafenib + Cetuximab + Pembrolizumab | 2     | mCRC MSI-H/dMMR | 104         | Not yet recruiting | No results posted  |
| NCT05231850   | Tislelizumab | 2     | CRC dMMR/MSI-H Stage II and III | 70          | No yet recruiting  | No results posted  |
| NCT05231850   | Tislelizumab | 2     | CRC dMMR/MSI-H Stage II and Stage III | 70          | No yet recruiting  | No results posted  |
### Table 1. Cont.

| Clinical Trial | Drug Treatment                  | Phase | Tumor Type                     | N. Patients | Status            | Conclusion         |
|----------------|--------------------------------|-------|--------------------------------|-------------|-------------------|--------------------|
| NCT04866862    | Fruquintinib + Camrelizumab    | 2     | Non MSI-H/dMMR Refractory CRC  | 32          | Not yet recruiting| No results posted  |
| NCT05131919    | Pembrolizumab                 | 2     | Locally advanced, Irresectable, dMMR not-mCRC | 25          | Not yet recruiting| No results posted  |
| NCT05215379    | Xintilimab injection          | 2-3   | Rectal cancer immunotherapy MSI-L | 180         | Not yet recruiting| No results posted  |

CRC: colorectal cancer; mCRC: metastatic CRC; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: microsatellite instability high; MSI-L: microsatellite instability low; dMMR: deficient mismatch repair; TMB: tumor mutational burden; POLE: DNA polymerase epsilon; ORR: objective response rate; PFS: progression free survival; PR: partial response; CR: complete response; RECIST: response evaluation criteria in solid tumors.

### Table 2. Comparison between IHC, PCR and NGS in CRC cases.

| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 28    | 16 dMMR     | 15 MSI-H    | 15 MSI      | [83]       |
|       | 12 pMMR     | 12 MSS      | 12 MSS      |            |
| 93    | 135 dMMR    | 132 MSI-H   | NP          | [84]       |
|       | 458 pMMR    | 4 MSI-H     | 10 MSI-L    |            |
|       |             | 444 MSS     |             |            |
| 988   | 102 dMMR    | 98 MSI-H    | NP          | [41]       |
|       | 886 pMMR    | 4 MSI-H     | 882 MSS/MSI-L |          |
| 91    | 54 dMMR     | 48 MSI-H    | 47 MSI      | [58]       |
|       | 37 pMMR     | 37 MSS/MSI-L | 37 MSS     |            |
| 73    | 12 dMMR     | 8 MSI-H     | 1 MSS       | [50]       |
|       | 61 pMMR     | 11 MSI-L    | 47 MSS      |            |
|       |             | 3 MSI-H     |             |            |
|       | 6 dMMR      | 6 MSI-H     | 6 MSI       | [86]       |
|       | 1 loMMR     | 1 MSI-H     | 1 MSI       |            |
|       | 1 paMMR     | 1 MSS       | 1 MSS       |            |
|       | 6 pMMR      | 6 MSS       | 1 MSI       |            |
|       | 1 NV        | 1 MSS       | 1 MSS       |            |
| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 262   | 28 dMMR     | 26 MSI-H    | NP          | [80]       |
|       |             | 2 MSI-L     |             |            |
|       | 234 pMMR    | 9 MSI-L     | 225 MSS     |            |
| 296   | 65 dMMR     | 63 MSI-H    | NP          | [82]       |
|       |             | 2 MSI-L     |             |            |
| 224   | 7 loMMR     | 5 MSI-H     |             |            |
|       |             | 2 MSI-L     |             |            |
| 98    | 38 dMMR     | 33 MSI-H    | 32 MSI-H    | [85]       |
|       |             | 1 MSS       | 1 MSS       |            |
|       |             | 1 MSI-L     | 1 MSS       |            |
|       |             | 4 MSS       | 4 MSS       |            |
| 60    | 60 pMMR     | 1 MSI-H     | 1 MSS       |            |
|       |             | 59 MSS      | 59 MSS      |            |
| 148   | 148 dMMR    | 147 MSI-H   |             |            |
|       |             | 1 MSS       |             |            |
| 809   | 12 loMMR    | 11 MSI-H    | NP          | [81]       |
|       |             | 1 MSS       |             |            |
| 649   | 649 pMMR    | 1 MSI-H     | 1 MSS       |            |
|       |             | 3 MSI-L     |             |            |
|       |             | 645 MSS     |             |            |
| 166   | 75 dMMR     | 75 MSI-H    |             |            |
| 91    | 91 pMMR     | 90 MSS/MSI-L| NP          | [87]       |
|       |             | 1 MSI-H     |             |            |

dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; IHC: immunohistochemistry; PCR: polymerase chain reaction; NGS: next generation sequencing; MSI-H: microsatellite instability-high; MSS: microsatellite stability; MSI-L: microsatellite instability-low; NP: not performed.

4. MSI in Gastric Cancer

The TCGA has included MSI status in the molecular classification of GC. Particularly, the TCGA classified GC in different molecular subsets, including the chromosome instability phenotypes (CIN), accounting for 50% of cases, the genomically stable (GS) tumors, accounting for 19%, the MSI phenotype, accounting for 22%, and the Epstein-Barr virus (EBV)-positive tumors, accounting for 9% (Figure 1) [88]. Although rare cases simultaneously carrying MSI and EBV have been identified, the TCGA considers MSI as a molecular profile distinct from the others [89]. Similarly, the Asian Cancer Research Group (ACRG) classified GC in MSS and MSI [90]. Many studies have found MSI in precancerous lesions and an increase in MSI frequency in GC cases is observed [91,92]. MSI GCs usually occur in older female patients, with an intestinal subtype at an early stage (I/II) and with better differentiation and distal position, and no lymph node involvement [44,91]. Ottini et al. observed that the MLH1 promoter methylation is frequently in sporadic GC, while MLH1 and MSH2 mutations are rare in MSI GCs [93]. MSI occurs both in sporadic GCs and in GCs associated with LS [94,95]. A positive correlation was observed between the presence of Helicobacter pylori (H. pylori) and MSI. The active bacterial infection is present more frequently in GC MSI patients, suggesting that H. pylori may affect the MMR system during the gradual progression of gastric carcinogenesis [52]. Approximately 85% of the MSI GC cases concomitantly showed a KRAS mutation. On the contrary, no association between
MSI GC and a mutated BRAF was reported [96]. MSI and human epidermal growth factor receptor 2 (HER2) amplification are reported to be mutually exclusive, suggesting that HER2 amplification could be a negative predictive marker for immunotherapy in GC patients [97]. The MSI status is not used as an exclusive prognostic biomarker, since the prognosis of GC patients is affected by other clinical and pathological features, including the age, stage, grade and chemotherapy treatment [98]. To date, controversial data about the prognostic role of MSI in GC have been reported. Several studies have shown that GCs carrying MSI have a good prognosis [91,99,100]. However, other studies showed MSI not having a prognostic role; in particular, MSI GCs do not have a better survival time than MSI-L/MSS patients. [101,102]. The metastatic MSI GCs have shown long-lasting positive results after receiving treatment with anti-PD-1 antibodies (durvalumab, pembrolizumab and nivolumab), as a single therapy or in combination with anti-CTLA4 antibodies (ipilimumab and tremelimumab) [103]. Pembrolizumab was investigated among patients with advanced MSI gastric or gastroesophageal junction cancer who were enrolled in different studies, such as KEYNOTE-059, KEYNOTE-061 and KEYNOTE-062. The results indicate that pembrolizumab or pembrolizumab plus chemotherapy provided durable antitumor activity compared to chemotherapy alone in patients with an MSI gastric junction or gastroesophageal cancer. Other clinical trials have suggested drug combinations, such as durvalumab and tremelimumab or nivolumab and ipilimumab in phase 2, for the treatment of advanced MSI GC [104–106] (Table 3). The comparative analysis between these methods showed some discrepancies, particularly as some dMMR-IHC cases were MSS by PCR (ranging from 1% to 38%) [51,107], while pMMR-IHC cases were MSI by molecular analysis (ranging from 1% to 7.4%) [52,108,109].

Table 3. Clinical trials for immune checkpoint inhibitors treatment of MSI GC.

| Clinical Trials | Drug Treatment | Phase | Tumor Type | N. Patients | Status | Conclusions |
|-----------------|----------------|-------|------------|-------------|--------|-------------|
| NCT04795661    | Pembrolizumab  | 2     | Localized resectable tumor MSI/dMMR or EBV-positive GC | 120        | Recruiting | No results posted |
| NCT04817826    | Durvalumab + Tremelimumab | 2 | GC MSI-H | 31        | Recruiting | No results posted |
| NCT05177133    | Capecitabine + Oxaliplatin + Retifanlimab | 2 | dMMR Esophagogastric cancer | 25 | Recruiting | No results posted |
| NCT04152889    | Camrelizumab + S-1 + Docetaxel | 2 | GC Stage III (PD-L1+/MSI-H/EBV+/dMMR) | 20 | Recruiting | No results posted |
| NCT04006262    | Nivolumab + Ipilimumab | 2 | Localized MSI and/or dMMR Oeso-gastric adenocarcinoma | 32 | Recruiting | No results posted |
| NCT03257163    | Capecitabine + Pembrolizumab + Radiation therapy | 2 | dMMR and Epstein–Barr virus Positive GC | 40 | Recruiting | No results posted |

GC: gastric cancer; MSI: microsatellite instability; MSI-H: microsatellite instability-high; dMMR: deficient mismatch repair; EBV: Epstein–Barr virus; PD-L1: programmed death-ligand 1.

The FDA accelerated approval of pembrolizumab in 2017 to treat MSI patients in solid tumors, including GC, who have progressed following prior treatment [27]. Few data have been reported regarding the MSI testing in GC; all the comparison data between IHC and PCR are summarized in Table 4.
Table 4. Comparison between IHC, PCR and NGS in GC cases.

| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 56    | 13 dMRR     | 8 MSI-H     | NP          | [107]      |
|       | 43 pMMR     | 5 MSI-L     |             |            |
| 580   | 61 dMRR     | 60 MSI-H    | NP          | [51]       |
|       | 519 pMMR    | 1 MSS       |             |            |
| 60    | 6 dMRR      | 6 MSI-H     | NP          | [52]       |
|       | 54 pMMR     | 4 MSI-H     | 50 MSS      |            |
| 16    | 9 dMMR      | 9 MSI-H     | NP          | [108]      |
|       | paMMR       | 1 MSI-H     |             |            |
|       | lo-paMMR    | 1 MSI-H     |             |            |
|       | 5 pMMR      | 5 MSS       |             |            |
| 50    | 4 dMMR      | 4 MSI-H     | NP          | [109]      |
|       | 46 pMMR     | 44 MSS      | 2 MSI-H     |            |

MMR: deficient mismatch repair; pMMR: proficient mismatch repair; IHC: immunohistochemistry; PCR: polymerase chain reaction; NGS: next generation sequencing; MSI-H: microsatellite instability-high; MSS: microsatellite stability; MSI-L: microsatellite instability-low; NP: not performed.

5. MSI in Gynecologic Cancers

Several studies have shown the presence of MSI from 2 to 20% in ovarian cancer (OC) (Figure 1), particularly in clear cell carcinomas and endometrioid cancers [110–112]. In clear cell carcinoma, the expression of CD8, PD-1 and tumor-infiltrating lymphocytes (TIL) was higher in MSI tumors than in those of MSS. In contrast, in endometrioid carcinomas, no correlation between the MSI status and TIL was reported [111,113]. MSI OCs are characterized by advanced stage, poor differentiation, grade and poor prognosis [114]. MSI OCs are frequently associated with LS [115]. However, the correlation between MSI and LS is not always verified since the LS was observed in both MSI OC and MSS OC [116]. MSI detection in OC has not yet been extensively studied and no adequate method is currently defined. The suitability and specificity of the Bethesda panel are still today an open issue in this cancer type [117]. There are few studies that have compared IHC and PCR for detecting MSI in OC (Table 5).

A concordance was shown between the IHC analysis and PCR [113]. Some discordant results have been observed; in particular, dMMR-IHC cases were MSS by PCR in a wide subset accounting from 1% to 80% [118–120]. Although MSI is still a poorly understood marker in OC patients, several studies showed its potential predictive role for ICI in this cancer (Table 6). The TCGA has included the MSI status in the molecular classification of endometrial cancer (EC). Particularly, the TCGA classified EC in different molecular subsets, including the no specific molecular profile (NSMP), accounting for 38% of cases, the MSI phenotype, accounting for 30%, the copy number high/mutant TP53 (CNH), accounting for 25%, and the POLE/ultramutated (POLE), accounting for 7% (Figure 1) [121–123]. Although some studies showed that some MSI EC cases also harbouring other mutations overlapped with different molecular phenotypes, the TCGA classified MSI EC as a distinct molecular phenotype [124]. LS in the EC was observed with a frequency of 3% [125].
Table 5. Comparison between IHC, PCR and NGS in OC cases.

| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 30    | 3 dMMR      | 3 MSI-H     | NP          | [113]      |
|       | 27 pMMR     | 27 MSS      |             |            |
| 834   | 228 dMMR    | 41 MSI-H    | NP          | [118]      |
|       | 606 pMMR    | 83 MSI-H    | 523 MSS     |            |
| 26    | 7 dMMR      | 7 MSI-H     |             | [119]      |
|       | 19 pMMR     | 1 MSI-H     |             |            |
| 42    | 4 dMMR      | 4 MSI-H     |             | [120]      |
|       | 38 pMMR     | 3 MSI-L     | 33 MSS      |            |

dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; IHC: immunohistochemistry; PCR: polymerase chain reaction; NGS: next generation sequencing; MSI-H: microsatellite instability-high; MSS: microsatellite stability; MSI-L: microsatellite instability-low; NP: not performed.

Table 6. Clinical trials for immune checkpoint inhibitors treatment of MSI OC.

| Clinical Trial | Drug Treatment | Phase | Tumor Type | N. Patients | Status | Conclusion |
|----------------|----------------|-------|------------|-------------|--------|------------|
| NCT03836352   | DPX-Survivac + Cyclophosphamide + Pembrolizumab vs. DPX-Survivac + Pembrolizumab | 2     | Solid tumors, including OC and MSI-H | 184 | Active, not recruiting | No results posted |

OC: ovarian cancer; MSI-H: microsatellite instability-high.

Regarding morphological features, MSI ECs are frequently characterized by the presence of peritumoral lymphocytes and TILs [126]. In approximately 95% of ECs, the MSI is due to the hypermethylation of the MLH1 promoter [127]. MSI ECs showed in about 10–53% of cases the simultaneous presence of other gene alterations, particularly the mutations of the following genes: RPL22 (46%) [128–130], PTEN (34%) [128,131], KRAS (35%) [128], ATR (15%) [132], CHK1 (29%) [133], Caspase5 (10%) [131,134] and BAX (27%) [129,134,135]. Furthermore, the PTEN gene mutations, frequently observed in sporadic EC (25–83%), showed a correlation with MSI with a frequency of 60% [136]. Moreover, MSI ECs are associated with a higher neoantigen load and increased TIL, CD3-positive, CD8-positive and PD-L-1 positive compared to MSS/pMMR EC [137]. The role of MSI in ECs is until now unclear; most of the studies have concluded that the MSI status has no prognostic role [138–140]. Previous studies have shown that the combination of pembrolizumab and lenvatinib can be used for second-line treatment in patients with EC who are not dMMR/MSI-H, and studies are ongoing for the treatment of patients with advanced EC MSI [141,142]. In the USA, both pembrolizumab and dostarlimab are approved as monotherapy for the treatment of MSI EC patients. In the EU, dostarlimab is the only therapy approved for patients with EC dMMR/MSI who have failed platinum therapy [143] (Table 7). Several studies have compared the different assays for MSI detection in EC series (Table 8).
Table 7. Clinical trials for immune checkpoint inhibitors treatment of MSI EC.

| Clinical Trial          | Drug Treatment                                                                 | Phase | Tumor Type          | N. Patients | Status          | Conclusion               |
|-------------------------|-------------------------------------------------------------------------------|-------|---------------------|-------------|-----------------|--------------------------|
| NCT04906382             | Carboplatin + Paclitaxel + Tislelizumab                                       | 1     | dMMR EC             | 20          | Recruiting      | No results posted        |
| NCT05112601             | Ipilimumab + Nivolumab vs. Nivolumab alone                                    | 2     | dMMR recurrent EC   | 12          | Recruiting      | No results posted        |
| NCT02912572             | Avelumab alone vs. Avelumab + Talazoparib vs. Avelumab + Axitinib             | 2     | mEC MSI-H           | 105         | Recruiting      | No results posted        |
| NCT04774419             | Intensity modulated radiation therapy (IMRT) + TSR-042                        | 2     | EC dMMR/MSI-H       | 31          | Recruiting      | No results posted        |
| NCT05036681             | Futibatinib vs. Pembrolizumab                                                 | 2     | MSS mEC            | 30          | Recruiting      | No results posted        |
| NCT05173987 Keynote C93 | Pembrolizumab alone vs. carboplatin + paclitaxel + docetaxel + cisplatin     | 3     | dMMR EC             | 350         | Recruiting      | No results posted        |
| NCT03241745             | Nivolumab                                                                     | 2     | EC dMMR/MSI-H       | 35          | Active, not recruiting | No results posted         |
| NCT05201547             | Dostarlimab alone vs. Carboplatin-Paclitaxel                                  | 3     | EC dMMR             | 142         | Not yet recruiting | No results posted        |

EC: endometrial cancer; mCRC: metastatic EC; MSS: microsatellite stability; dMMR: deficient mismatch repair.

Table 8. Comparison between IHC, PCR and NGS in EC cases.

| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 108   | 33 dMMR     | 27 MSI-H    | NP          | [144]      |
|       | 75 pMMR     | 75 MSS      |             |            |
| 98    | 18 dMMR     | 8 MSI-H     | NP          | [145]      |
|       | 5 loMMR     | 2 MSI-H     |             |            |
|       | 75 pMMR     | 75 MSS      |             |            |
| 52    | 52 dMMR     | 51 MSI-H    | 1 MSS       |            |
| 100   | 10 loMMR    | 6 MSI-H     | 4 MSS       | [146]      |
|       | 9 paMMR     | 3 MSI-H     |             |            |
|       | 18 pMMR     | 1 MSI-L     | 5 MSS       |            |
|       | 11 NA       | 8 MSI-H     | 3 MSS       |            |
Table 8. Cont.

| Cases | IHC Results | PCR Results | NGS Results | References |
|-------|-------------|-------------|-------------|------------|
| 89    | 26 dMMR     | 23 MSI-H    | NP          | [147]      |
|       |             | 3 MSS       |             |            |
|       | 63 pMMR     | 3 MSI-H     | 16 MSI      |            |
|       |             |             | 13 MSS      | [148]      |
| 99    | 29 dMMR     | NA          | 2 MSI       |            |
|       |             |             | 68 MSS      |            |
| 21    | 9 dMMR      | 6 MSI-H     | 8 MSI       | [83]       |
|       |             | 2 MSS       |             |            |
|       | 3 loMMR     | 1 MSI-L     | 1 MSS       |            |
|       |             | 2 MSS       | 2 MSS       |            |
|       | 9 pMMR      | 1 MSI-H     | 1 MSI       |            |
|       |             | 9 MSS       | 9 MSS       |            |
| 15    | 6 dMMR      | 5 MSI-H     | 6 MSI       | [86]       |
|       |             | 1 NA        |             |            |
|       | 3 loMMR     | 2 MSI-H     | 1 MSI       |            |
|       |             | 1 MSI       | 1 MSS       |            |
|       | 1 paMMR     | 1 MSS       | 1 MSS       |            |
|       | 5 pMMR      | 5 MSS       | 5 MSS       |            |

dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; IHC: immunohistochemistry; PCR: polymerase chain reaction; NGS: next generation sequencing; MSI-H: microsatellite instability-high; MSS: microsatellite stability; MSI-L: microsatellite instability-low; NA: not available; NP: not performed.

The comparative analysis between these methods showed some discrepancies; in particular, approximately 1–68% of dMMR-IHC cases were MSS by PCR/NGS [83,86,144–146], and about 5% of pMMR-IHC cases were MSI-H by molecular analysis [147,148].

6. MSI in Other Malignancies

MSI has been found in several cancer types, including non-small cell lung cancer, melanoma, breast cancer, uterine cancer, pancreatic ductal adenocarcinoma and brain cancer. The expansion of MSI clinical trials into other cancers may elucidate the prognostic and predictive value of MSI for non-colorectal. The frequency of MSI reported in non-small cell lung cancer (NSCLC) is very heterogeneous, ranging from 0.8% to 40% [149–152]. The role and clinical implications of MSI are still unclear in NSCLC. Carpagnano et al. suggested that MSI is associated with a poor prognosis in NSCLC [153].

Moreover, recent findings suggested that MSI in NSCLC is associated with an increased response to immunotherapy [154]. Several clinical trials showed the efficacy of pembrolizumab for the treatment of previously treated NSCLC patients carrying MSI [155–157] (Table 9).
Table 9. Clinical trials for immune checkpoint inhibitors treatment of other MSI/no-MSI-H tumors.

| Clinical Trial         | Drug Treatment                          | Phase | Tumor Type                                                                 | N. Patients | Status          | Conclusion                                                                 |
|-----------------------|-----------------------------------------|-------|----------------------------------------------------------------------------|-------------|-----------------|----------------------------------------------------------------------------|
| NCT01876511 KEYNOTE-016 | Pembrolizumab                           | 2     | MSI CRC, MSS CRC, MSI Non-CRC                                              | 113         | Completed       | ORR: disappearance of all target lesions; PR: 30% decrease in the diameters of the target lesions. |
| NCT04328740           | TP-1454 monotherapy vs. TP-1454 + Iplilimumab + Nivolumab | 1     | Advanced solid tumor, Advanced/metastatic RCC, MSI-H or dMMR mCRC, NSCLC | 44          | Recruiting      | No results posted                                                          |
| NCT02332668 KEYNOTE-051 | Pembrolizumab                           | 1–2   | Melanoma, Lymphoma, Solid tumor, Classical Hodgkin Lymphoma; MSI-H solid tumor | 320         | Recruiting      | No results posted                                                          |
| NCT04521075           | Fecal microbial transplantation by capsules | 1–2   | Metastatic or inoperable melanoma, MSI-H, dMMR or NSCLC                    | 42          | Recruiting      | No results posted                                                          |
| NCT03607890           | Nivolumab + Relatlimab                   | 2     | Advanced dMMR cancers resistant to Prior PD-(L)1 inhibitor                 | 42          | Recruiting      | No results posted                                                          |
| NCT03667170           | Envafolimab                              | 2     | dMMR/MSI-H advanced solid tumors                                          | 200         | Recruiting      | No results posted                                                          |
| NCT03236935           | L-NMMA + Pembrolizumab                   | 1     | NSCLC, Malignant melanoma, Head and neck squamous cell carcinoma, Classical Hodgkin Lymphoma, Urothelial carcinoma, Bladder, DNA repair-deficiency disorders | 12          | Active, not recruiting | No results posted                                                          |
| NCT03053466           | APL-501                                 | 1     | Solid tumors MSI-H or dMMR                                                | 30          | Active, not recruiting | No results posted                                                          |
| NCT04800627           | Pembrolizumab + Pevonedistat             | 1–2   | dMMR/MSI-H metastatic or locally advanced unresectable solid tumor         | 2           | Active, not recruiting | No results posted                                                          |
| NCT02983578           | Danvatirsen + Durvalumab                 | 2     | Advanced and refractory pancreatic, NSCLC and dMMR CRC                   | 53          | Active, not recruiting | No result posted                                                            |
| NCT03241745           | Nivolumab                                | 2     | MSI/dMMR/Hypermutated uterine cancer                                       | 35          | Active, not recruiting | No results posted                                                          |
| NCT04326829           | QL1604                                  | 2     | dMMR or MSI-H advanced solid tumors                                       | 86          | Not yet recruiting | No results posted                                                          |

CRC: colorectal cancer; mCRC: metastatic CRC; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: microsatellite instability-high; dMMR: deficient mismatch repair; RCC: renal cell carcinoma; NSCLC: non-small cell lung cancer; ORR: objective response rate; PFS: progression free survival; OS: overall survival; PR: partial response; RECIST: response evaluation criteria in solid tumors.
MSI is extremely rare in breast cancer, showing a frequency of 0.04–3% [158,159]. However, MSI was observed in triple negative breast cancer (TNBC), with a high frequency accounting for between approximately 0.2% and 18.6% [160–162]. The role of MSI in BC is still uncertain. Some studies have shown that MSI does not have a significant impact on patient survival [149]. Conversely, other studies have reported a positive prognostic value of MSI in TNBC [160]. A significant correlation was observed between MSI and the negative expression of estrogen and progesterone receptors, indicating a possible relationship between genetic changes in microsatellite regions and hormonal deregulation in the progression of BC [163]. In BC, MSI showed a correlation with the advanced clinical stage, the tumor size and the high grade [164]. The KEYNOTE-028 and KEYNOTE-012 studies demonstrated the efficacy of pembrolizumab in BC previously treated with CDK4/6 inhibitors. [158,165]. The pancreatic ductal adenocarcinoma (PDAC) showed MSI in about 1–2% [166,167]. PDACs carrying MSI are generally associated with LS [168]. LS-associated pancreatic tumors, ranging from 0.5% to 3.9%, are generally associated with medullary histology showing prominent lymphocyte infiltration [167,169]. PDAC is an aggressive type of human cancer; moreover, most patients are resistant to chemotherapy. Thus, immunotherapy could be a possible therapeutic option [170]. Previous studies showed that pMMR PDCA patients treated with conventional chemotherapy have a survival advantage compared to dMMR patients, suggesting that MSI can be considered a potential predictor of treatment sensitivity [171–173]. KEYNOTE-016 evaluated the efficacy of pembrolizumab in eight cases of MSI PDAC, showing a complete response in two patients and a partial response in three patients [27,174]. These preliminary results suggested that anti-PD-L1 antibody treatment could be effective in patients with MSI PDAC. MSI was reported in approximately 10–15% of thyroid carcinomas (TC) [175–177]; moreover, a correlation between MSI and clinical-pathological features was observed. Particularly, MSI TCs were generally papillary or anaplastic and poorly differentiated histotypes. A recent study showed that MSI TC patients have a good prognosis compared to MSS TC [177]. Although several clinical trials are being evaluated for the efficacy of pembrolizumab, nivolumab and atezolizumab in MSI TC, until now no immunological therapy has been approved for MSI TC [178,179]. The ICI targeting the PD-1/PD-L1 pathway may be a treatment option for MSI TC; however, further studies are needed [177]. The frequency of MSI brain tumors is very low, ranging from 2% to 3% of cases [27,116]. Brain tumors are rarely associated with LS (0.5–3.7% of all cases). No information is available regarding the specific molecular or phenotypic characteristics of LS-related brain tumors [167]. The MSI phenotype was observed in about 25% of glioblastomas (GBM) [180]. MSI GBM showed a low level of PD-L1 expression, suggesting it is not a good predictive marker for ICI targeting the PD1/PD-L1 pathway [181]. MSI has been shown to occur in malignant melanomas, with a frequency of between 2 and 30% [182–184]. Kubecek et al. suggested that MSI might be a predictive marker in malignant melanoma [185]. Although the KEYNOTE-016 study showed the efficacy of pembrolizumab in MSI melanomas that have progressed after previous treatment, the treatment for MSI melanoma is not yet used in clinical practice [27].

MSI has been identified in approximately 1–28% of urothelial carcinomas (UC) [186–188]. The upper tract urothelial carcinomas (UTUCs) also occur in about 5% of patients with LS [189]. The heterodimer MSH2/MSH6 is frequently lost in the UTUC in about 50–86% of cases [186,190,191]. Several studies reported that UTUCs MSI showed unique morphological features compared to MSS UTUC, including increased intratumoral lymphocytes, the lack of nuclear pleomorphism and the presence of pushing edges [167,190,192]. The KEYNOTE-158 study demonstrated the benefit of pembrolizumab treatment in patients carrying MSI-H/dMMR including UCs [174]. The prostate cancers (PCs) showed MSI status in 1.2–12% of cases. MSI PCs represent a clinically aggressive phenotype [193]. The germline alterations in the MMR genes are less common in localized PC, suggesting an increase in mutations in patients with metastatic spread [194]. In the KEYNOTE-016 study, MSI PCs responded better to ICI [27]. Although MSI can be considered a biomarker capable of responding to
immunotherapy in prostate cancer, ICIs are not yet used in clinical practice for the treatment of metastatic PCs [195].

7. Conclusions

The MMR system is a key repair mechanism for maintaining sequence fidelity and stability. The inactivation of the MMR system due to the germinal, somatic or epigenetic prevents error correction and, thus, promotes microsatellite instability. MSI has been detected in various cancers with a prognostic and/or predictive role; in particular, it is clinically important for predicting a response to immunotherapy. MSI represents the FDA’s first cancer type-agnostic biomarker approved for selection to the treatment with pembrolizumab of patients with any advanced solid cancer, regardless of the histology. The results reported underline the pivotal role of MSI in the choice of drug treatment in patients, especially in the cases of those who no longer respond to chemotherapy. To date, MSI detection aimed at selecting patients for ICI treatment could be performed through both IHC and PCR/NGS. Although the two tests are equated in clinical practice for the therapeutic choice, several controversial results have been reported. In this view, the optimization of MSI detection in clinical practice is currently needed in order to implement an adequate selection of patients eligible for ICI treatment of dMMR tumors. A feasible diagnostic algorithm for MSI testing could include IHC as prescreening requiring an additional molecular test for cases with an equivocal IHC of one or more MMR proteins, and also to confirm dMMR cases in order to exclude false IHC results.

Author Contributions: Conceptualization, M.A. (Marina Accardo) and F.Z.M.; writing—original draft preparation, M.A. (Martina Amato), M.A. (Marina Accardo), F.Z.M. and R.F.; review and editing, R.A., F.C., M.A. (Marina Accardo), G.V., A.S., G.F., M.B., S.P. and M.C.; supervision, F.Z.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Li, K.; Luo, H.; Huang, L.; Luo, H.; Zhu, X. Microsatellite instability: A review of what the oncologist should know. *Cancer Cell Int.* 2020, 20, 16. [CrossRef]
2. Hause, R.J.; Pritchard, C.C.; Shendure, J.; Salipante, S.J. Classification and characterization of microsatellite instability across 18 cancer types. *Nat. Med.* 2016, 22, 1342–1350. [CrossRef]
3. Kawka, M.; Parada, R.; Jaszczyk, K.; Horbańczuk, J.O. The use of microsatellite polymorphism in genetic mapping of the ostrich (*Struthio camelus*). *Mol. Biol. Rep.* 2012, 39, 3369–3374. [CrossRef]
4. Bastos-Rodrigues, L.; Pimenta, J.R.; Pena, S.D.J. The Genetic Structure of Human Populations Studied Through Short Insertion-Deletion Polymorphisms. *Ann. Hum. Genet.* 2006, 70, 658–665. [CrossRef]
5. Sturzeneker, R.; Bevilacqua, R.A.; Haddad, L.A.; Simpson, A.J.; Pena, S.D. Microsatellite instability in tumors as a model to study the process of microsatellite mutations. *Hum. Mol. Genet.* 2000, 9, 347–352. [CrossRef]
6. Eso, Y.; Shimizu, T.; Takeda, H.; Takai, A.; Marusawa, H. Microsatellite instability and immune checkpoint inhibitors: Toward pre-cision medicine against gastrointestinal and hepatobiliary cancers. *J. Gastroenterol.* 2020, 55, 15–26. [CrossRef]
7. Jiricny, J. The multifaceted mismatch-repair system. *Nat. Rev. Mol. Cell Biol.* 2006, 7, 335–346. [CrossRef]
8. Bonneville, R.; Krook, M.A.; Chen, H.Z.; Smith, A.; Samorodnitsky, E.; Wing, M.R.; Reeser, J.W.; Roychowdhury, S. Detection of Mi-crosatellite Instability Biomarkers via Next-Generation Sequencing. *Methods Mol. Biol.* 2020, 2055, 119–132.
9. Lochhead, P.; Kuchiba, A.; Imamura, Y.; Liao, X.; Yamauchi, M.; Nishihara, R.; Qian, Z.R.; Morikawa, T.; Shen, J.; Meyerhardt, J.A.; et al. Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication. *J. Natl. Cancer Inst.* 2013, 105, 1151–1156. [CrossRef]
10. Ligtenberg, M.J.; Kuiper, R.P.; Chan, T.L.; Goossens, M.; Hebeda, K.M.; Voorendt, M.; Lee, T.Y.; Bodmer, D.; Hoenselaar, E.; Hendriks-Cornelissen, S.J.; et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. *Nat. Genet.* 2009, 41, 112–117. [CrossRef]
11. Edwards, R.A.; Witherspoon, M.; Wang, K.; Afrasiabi, K.; Pham, T.; Birnbaumer, L.; Lipkin, S.M. Epigenetic repression of DNA mis-match repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. *Cancer Res.* 2009, 69, 6423–6429. [CrossRef]

12. Yamamoto, H.; Adachi, Y.; Taniguchi, H.; Kunimoto, H.; Nosho, K.; Suzuki, H.; Shinomura, Y. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. *World J. Gastroenterol.* 2012, 18, 2745–2755. [CrossRef]

13. Lai, Y.; Sun, F. The relationship between microsatellite slippage mutation rate and the number of repeat units. *Mol. Biol. Evol.* 2003, 20, 2123–2131. [CrossRef]

14. Gologan, A.; Sepulveda, A.R. Microsatellite Instability and DNA Mismatch Repair Deficiency Testing in Hereditary and Sporadic Gastrointestinal Cancers. *Clin. Lab. Med.* 2005, 25, 179–196. [CrossRef]

15. Yurgelun, M.B.; Kastrinos, F. Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights into an Old Diagnostic Strategy. *J. Clin. Oncol.* 2019, 37, 263–265. [CrossRef]

16. Dominguez-Valentin, M.; Sampson, J.R.; Seppälä, T.T.; Ten Broeke, S.W.; Plazzer, J.P.; Nakken, S.; Engel, C.; Aretz, S.; Jenkins, M.A.; Sundé, L.; et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. *Genet. Med.* 2020, 22, 15–25. [CrossRef]

17. Bucksh, K.; Zachariae, S.; Arețz, S.; Büttrn, R.; Holinski-Feder, E.; Holzapfel, S.; Hüneg, R.; Kloor, M.; von Doerberitz, M.K.; Morak, M.; et al. Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: A prospective cohort study. *BMC Cancer* 2020, 20, 460. [CrossRef]

18. Kim, T.-M.; Laird, P.W.; Park, P.J. The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes. *Cell* 2013, 155, 858–868. [CrossRef]

19. Oda, S.; Maehara, Y.; Ikeda, Y.; Oki, E.; Egashira, A.; Okamura, Y.; Takahashi, I.; Kakeji, Y.; Sumiyoshi, Y.; Miyashita, K.; et al. Two modes of microsatellite insta-bility in human cancer: Differential connection of defective DNA mismatch repair to dinucleotide repeat instability. *Nucleic Acids Res.* 2005, 33, 1628–1636. [CrossRef]

20. Thibodeau, S.N.; Bren, G.; Schaid, D. Microsatellite Instability in Cancer of the Proximal Colon. *Science* 1993, 260, 816–819. [CrossRef]

21. De la Chapelle, A.; Hampel, H. Clinical relevance of microsatellite instability in colorectal cancer. *J. Clin. Oncol.* 2010, 28, 3380–3387. [CrossRef]

22. Pritchard, C.C.; Morrissey, C.; Kumar, A.; Zhang, X.; Smith, C.; Coleman, I.; Salipante, S.J.; Milbank, J.; Yu, M.; Grady, W.M.; et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. *Nat. Commun.* 2014, 5, 4988. [CrossRef]

23. Dudley, J.C.; Lin, M.-T.; Le, D.T.; Eshleman, J.R. Microsatellite Instability as a Biomarker for PD-1 Blockade. *Clin. Cancer Res.* 2016, 22, 813–820. [CrossRef]

24. Takahashi, Y.; Kondo, K.; Hirose, T.; Nakagawa, H.; Tsuyuguchi, M.; Hashimoto, M.; Sano, T.; Ochiai, A.; Monden, Y. Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromatexposed workers. *Mol. Carcinog.* 2005, 42, 150–158. [CrossRef]

25. Alvino, E.; Marra, G.; Pagani, E.; Falcinelli, S.; Peponi, R.; Perren, C.; Haider, R.; Castiglia, D.; Ferranti, G.; Bonmassar, E.; et al. High-Frequency Microsatellite Instability is Associated with Defective DNA Mismatch Repair in Human Melanoma. *J. Investig. Dermatol.* 2002, 118, 79–86. [CrossRef]

26. Kassem, H.S.; Varley, J.M.; Hamam, S.M.; Margison, G.P. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. *Br. J. Cancer* 2001, 84, 321–328. [CrossRef]

27. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science 2017*, 357, 409–413. [CrossRef]

28. Jover, R.; Zapatier, P.; Castells, A.; Llor, X.; Andreu, M.; Cubiella, J.; Balaguer, F.; Sempere, L.; Xicola, R.M.; Bujanda, L.; et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. *Eur. J. Cancer* 2009, 45, 365–373. [CrossRef]

29. Nikanjam, M.; Arguello, D.; Gatalica, Z.; Swensen, J.; Barkauskas, D.A.; Kurzrock, R. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. *Int. J. Cancer* 2019, 146, 3087–3097. [CrossRef]

30. Drescher, K.M.; Sharma, P.; Watson, P.; Gatalica, Z.; Thibodeau, S.N.; Lynch, H.T. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. *Fam. Cancer* 2009, 8, 231–239. [CrossRef]

31. Llorente, C.; Cruise, M.; Tam, A.; Wicks, E.C.; Hechenleitner, E.M.; Taube, J.M.; Blosser, R.L.; Fan, H.; Wang, H.; Luber, B.S.; et al. The vigorous immune microenviroment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov.* 2015, 5, 43–51. [CrossRef]

32. Ma, C.; Patel, K.; Singh, A.; Ren, B.; Zhu, H.; Shaikh, F.; Sun, W. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated with Epstein-Barr Virus or Microsatellite Instability. *Am. J. Surg. Pathol.* 2016, 40, 1496–1506. [CrossRef]

33. Bai, W.; Ma, J.; Liu, Y.; Liang, J.; Wu, Y.; Yang, X.; Xu, E.; Li, Y.; Xi, Y. Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. *Cancer Med.* 2019, 8, 2157–2166. [CrossRef]

34. Zeng, Z.; Yang, B.; Liao, Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. *Front. Oncol.* 2021, 11, 650481. [CrossRef]
35. Marginean, E.C.; Melosky, B. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I: Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. *Arch. Pathol. Lab. Med.* 2018, 142, 17–25. [CrossRef]

36. Pearlman, R.; Markow, M.; Knight, D.; Chen, W.; Arnold, C.A.; Pritchard, C.C.; Hampel, H.; Frankel, W.L. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. *Mod. Pathol.* 2018, 31, 1891–1900. [CrossRef]

37. Chen, W.; Swanson, B.J.; Frankel, W.L. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. *Diagn. Pathol.* 2017, 12, 24. [CrossRef]

38. Rigau, V.; Sebbagh, N.; Olschwang, S.; Paraf, F.; Mourra, N.; Parc, Y.; Flejou, J.F. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. *Arch. Pathol. Lab. Med.* 2003, 127, 694–700. [CrossRef]

39. Beamer, L.; Grant, M.L.; Espenschied, C.; Blazer, K.R.; Hampel, H.L.; Weitzel, J.N.; Macdonald, D.J. Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome Among US Cancer Programs and Follow-Up of Abnormal Results. *J. Clin. Oncol.* 2012, 30, 1058–1063. [CrossRef]

40. Hampel, H. Point: Justification for Lynch Syndrome Screening Among All Patients with Newly Diagnosed Colorectal Cancer. *J. Natl. Compr. Cancer Netw.* 2010, 8, 597–601. [CrossRef]

41. Berardinelli, G.N.; Scapulatempo-Neto, C.; Durães, R.; de Oliveira, M.A.; Guimarães, D.; Reis, R.M. Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. *Oncotarget* 2018, 9, 28691–28701. [CrossRef] [PubMed]

42. Bacher, J.W.; Sievers, C.K.; Albrecht, D.M.; Grimes, I.C.; Weiss, J.; Matkowskyj, K.A.; Agni, R.M.; Vyazunova, I.; Clipson, L.; Storts, U.R.; et al. Improved Detection of Microsatellite Instability in Early Colorectal Lesions. *PLoS ONE* 2015, 10, e0132727. [CrossRef]

43. McCarthy, A.J.; Capo-Chichi, J.M.; Spence, T.; Grenier, S.; Stockley, T.; Kamel-Reid, S.; Serra, S.; Sabatini, P.; Chey, T. Heterogenous loss of mismatch repair (MMR) protein expression: A challenge for immunohistochemical interpretation and microsatellite in-stability (MSI) evaluation. *J. Pathol. Clin. Res.* 2019, 5, 115–129. [CrossRef]

44. Mathiak, M.; Warneke, V.S.; Behrens, H.M.; Haag, J.; Böger, C.; Krüger, S.; Röcken, C. Clinicopathologic Characteristics of Microsatel-lite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization. *Appl. Immunohistochem. Mol. Morphol.* 2017, 25, 12–24. [CrossRef]

45. Bartley, A.N.; Luthra, R.; Saraiya, D.S.; Urbauer, D.L.; Broaddus, R.R. Identification of cancer patients with Lynch syndrome: Clinically significant discordances and problems in tissue-based mismatch repair testing. *Cancer Res. Pathol. Res.* 2012, 5, 320–327. [CrossRef]

46. Suraweera, N.; Duval, A.; Reperant, M.; Vaury, C.; Furlan, D.; Leroy, K.; Seruca, R.; Iacopetta, B.; Hamelin, R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology* 2002, 123, 1804–1811. [CrossRef]

47. Campanella, N.C.; Berardinelli, G.N.; Scapulatempo-Neto, C.; Viana, D.; Palmero, E.I.; Pereira, R.; Reis, R.M. Optimization of a penta-plex panel for MSI analysis without control DNA in a Brazilian population: Correlation with allele markers. *Eur. J. Hum. Genet.* 2014, 22, 875–880. [CrossRef]

48. Umar, A.; Risinger, J.I.; Hawk, E.T.; Barrett, J.C. Testing guidelines for hereditary non-polyposis colorectal cancer. *Nat. Cancer* 2004, 4, 153–158. [CrossRef]

49. Murphy, K.M.; Zhang, S.; Geiger, T.; Hafez, M.J.; Bacher, J.; Berg, K.D.; Eshleman, J.R. Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers. *J. Mol. Diagn.* 2006, 8, 305–311. [CrossRef]

50. Cheah, P.L.; Li, J.; Looi, L.M.; Koh, C.C.; Lau, T.P.; Chang, S.W.; Teoh, K.H.; Mun, K.S.; Nazarina, A.R. Screening for microsatellite instability in colorectal cancer: Practical utility of immunohistochemistry and microsatellite PCR with fragment analysis in a diagnostic histopathology setting. *Malays. J. Pathol.* 2019, 41, 91–100. [CrossRef]

51. Cho, J.; Kang, S.Y.; Kim, K.-M. MMR protein immunohistochemistry and microsatellite instability in gastric cancers. *Pathology* 2018, 51, 110–113. [CrossRef] [PubMed]

52. Haron, N.H.; Mohamad Hanif, E.A.; Abdul Manaf, M.R.; Yaakub, J.A.; Harun, R.; Mohamed, R.; Mohamed Rose, I. Microsatellite In-stability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer. *Asian Pac. J. Cancer Prev.* 2019, 20, 509–517. [CrossRef] [PubMed]

53. Salipante, S.J.; Scroggins, S.M.; Hampel, H.L.; Turner, E.H.; Pritchard, C.C. Microsatellite instability detection by next generation se-sequencing. *Clin Chem.* 2014, 60, 1192–1199. [CrossRef] [PubMed]

54. Lu, Y.; Soong, T.D.; Elemento, O. A Novel Approach for Characterizing Microsatellite Instability in Cancer Cells. *PLoS ONE* 2013, 8, e63056. [CrossRef] [PubMed]

55. Niu, B.; Ye, K.; Zhang, Q.; Lu, C.; Xie, M.; McLellan, M.D.; Wendl, M.C.; Ding, L. MSIsensor: Microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics* 2013, 30, 1015–1016. [CrossRef]

56. Kautto, E.A.; Bonneville, R.; Miya, J.; Yu, L.; Krook, M.A.; Reeser, J.W.; Roychowdhury, S. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. *Oncotarget* 2016, 7, 7452–7463. [CrossRef]
79. Lenz, H.-J.; Van Cutsem, E.; Limon, M.L.; Wong, K.Y.M.; Hendliosz, A.; Aglietta, M.; García-Alfonso, P.; Neyns, B.; Luppi, G.; Cardin, D.B.; et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J. Clin. Oncol. 2022, 40, 161–170. [CrossRef] [PubMed]

80. Hatch, S.B.; Lightfoot, H.M., Jr; Garwacki, C.P.; Moore, D.T.; Calvo, B.F.; Woosley, J.T.; Sciarrotta, J.; Funkhouser, W.K.; Farber, R.A. Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch re-pair-deficient tumors. Clin. Cancer Res. 2005, 11, 2180–2187. [CrossRef]

81. Hissong, E.; Crowe, E.P.; Yantiss, R.K.; Chen, Y.-T. Assessing colorectal cancer mismatch repair status in the modern era: A survey of current practices and re-evaluation of the role of microsatellite instability testing. Mod. Pathol. 2018, 31, 1756–1766. [CrossRef] [PubMed]

82. Yuan, L.; Chi, Y.; Chen, W.; Chen, X.; Wei, P.; Sheng, W.; Zhou, X.; Shi, D. Immunohistochemistry and microsatellite instability analysis in molecular typing of colorectal carcinoma based on mismatch repair competency. Int. J. Clin. Exp. Med. 2015, 8, 20988–21000. [PubMed]

83. Dedeurwaerdere, F.; Claes, K.B.; Van Dorpe, J.; Rottiers, I.; Van der Meulen, J.; Breyne, J.; Swaerts, K.; Martens, G. Comparison of mi-crosatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci. Rep. 2011, 11, 12880. [CrossRef] [PubMed]

84. Loughrey, M.B.; McGrath, J.; Coleman, H.G.; Bankhead, P.; Maxwell, P.; McGready, C.; Bingham, V.; Humphries, M.P.; Craig, S.G.; McQuaid, S.; et al. Identifying mismatch repair-deficient colon cancer: Near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology 2021, 78, 401–413. [CrossRef]

85. Hissong, E.; Crowe, E.P.; Yantiss, R.K.; Chen, Y.-T. Assessing colorectal cancer mismatch repair status in the modern era: A survey of current practices and re-evaluation of the role of microsatellite instability testing. Mod. Pathol. 2018, 31, 1756–1766. [CrossRef] [PubMed]

86. Yuan, L.; Chi, Y.; Chen, W.; Chen, X.; Wei, P.; Sheng, W.; Zhou, X.; Shi, D. Immunohistochemistry and microsatellite instability analysis in molecular typing of colorectal carcinoma based on mismatch repair competency. Int. J. Clin. Exp. Med. 2015, 8, 20988–21000. [PubMed]

87. Dedeurwaerdere, F.; Claes, K.B.; Van Dorpe, J.; Rottiers, I.; Van der Meulen, J.; Breyne, J.; Swaerts, K.; Martens, G. Comparison of mi-crosatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci. Rep. 2011, 11, 12880. [CrossRef] [PubMed]

88. Zhang, W. TCGA divides gastric cancer into four molecular subtypes: Implications for individualized therapeutics. Chin. J. Cancer 2014, 33, 469–470. [CrossRef]

89. Yu, W.; Wu, Y.; Jin, M.; Jia, Z.; Wang, Y.; Cao, D.; Qin, L.; Wang, X.; Zheng, M.; Cao, X.; et al. Microsatellite instability and Ep-stein-Barr virus combined with PD-L1 expression can serve as a potential strategy for predicting the prognosis and efficacy of post-erative chemotherapy in gastric cancer. PeerJ 2021, 9, e11481. [CrossRef]

90. Cristescu, R.; Lee, J.; Nebozhyn, M.; Kim, K.-M.; Ting, J.C.; Wong, S.S.; Liu, J.; Yue, Y.G.; Wang, J.; Yu, K.; et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 2015, 21, 449–456. [CrossRef]

91. Zhao, W.; Chan, T.L.; Chu, K.-M.; Chan, A.S.; Stratton, M.R.; Yuen, S.T.; Leung, S.Y. Mutations ofBRAF andKRAS in gastric cancer with microsatellite instability. Ann. Oncol. 2011, 22, 161–170. [CrossRef]

92. Sugimoto, R.; Sugai, T.; Habano, W.; Endoh, M.; Eizuka, M.; Yamamoto, E.; Uesugi, N.; Ishida, K.; Kawasaki, T.; Matsumoto, T.; et al. Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype. Int. J. Cancer 2015, 138, 1689–1697. [CrossRef]

93. Ottini, L.; Falchetti, M.; Lupi, R.; Rizzolo, P.; Agnese, V.; Colucci, G.; Bazan, V.; Russo, A. Patterns of genomic instability in gastric cancer: Clinical implications and perspectives. Ann. Oncol. 2006, 17, vii97–viii102. [CrossRef]

94. Corso, G.; Velho, S.; Paredes, J.; Pedrazzani, C.; Martins, D.; Milanesi, F.; Pascale, V.; Vindigni, C.; Pinheiro, H.; Leite, M.; et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur. J. Cancer 2011, 47, 443–451. [CrossRef]

95. Hudler, P. Genetic Aspects of Gastric Cancer Instability. Sci. World J. 2012, 2012, 761909. [CrossRef]

96. Zhao, W.; Chan, T.L.; Chu, K.-M.; Chan, A.S.; Stratton, M.R.; Yuen, S.T.; Leung, S.Y. Mutations ofBRAF andKRAS in gastric cancer and their association with microsatellite instability. Int. J. Cancer 2003, 103, 167–169. [CrossRef]

97. Huang, H.; Wang, Z.; Li, Y.; Zhao, Q.; Niu, Z. Amplification of the human epidermal growth factor receptor 2 (HER2) gene is as-soicated with a microsatellite stable status in Chinese gastric cancer patients. J. Gastrointest. Oncol. 2021, 12, 377–387. [CrossRef]

98. Polom, K.; Marano, L.; Marrelli, D.; DE Luca, R.; Roviello, G.; Savelli, V.; Pan, P. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br. J. Surg. 2017, 105, 159–167. [CrossRef]

99. Cai, L.; Sun, Y.; Wang, K.; Guan, W.; Yue, J.; Li, J.; Wang, R.; Wang, L. The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer. Front. Oncol. 2020, 10, 1269. [CrossRef]

100. Zhang, Q.; Wang, L.; Ni, S.; Tan, C.; Cai, X.; Huang, D.; Sheng, W. Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer. Int. J. Clin. Exp. Pathol. 2018, 11, 2579–2587. [CrossRef]

101. An, J.Y.; Kim, H.; Cheong, J.-H.; Hyung, W.J.; Kim, H.; Noh, S.H. Microsatellite instability in sporadic gastric cancer: Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int. J. Cancer 2011, 131, 505–511. [CrossRef] [PubMed]
102. Smyth, E.C.; Wotherspoon, A.; Peckitt, C.; Gonzalez, D.; Hulki-Wilson, S.; Eltaher, Z.; Fassan, M.; Rugge, M.; Valeri, N.; Okines, A.; et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. *JAMA Oncol.* 2017, 3, 1197–1203. [CrossRef] [PubMed]

103. Janjigian, Y.Y.; Sanchez-Vega, F.; Jonsson, P.; Chatila, W.K.; Hechtman, J.F.; Ku, G.Y.; Riches, J.C.; Tuvy, Y.; Kundra, R.; Bourvier, N.; et al. Genetic Predictors of Response to Systemic Therapy in Esophageal Cancer. *Cancer Discov.* 2018, 8, 49–58. [CrossRef]

104. Cohen, R.; Pudlazar, T.; Garcia-Larnicol, M.L.; Vernerey, D.; Dray, X.; Clavel, L.; Jary, M.; Piessen, G.; Zaanan, A.; Aparicio, T.; et al. Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NE-ONIPiGA phase II study is opened to recruitment. *Bull Cancer* 2020, 107, 438–446. [CrossRef] [PubMed]

105. Raimondi, A.; Palermo, F.; Prisciandaro, M.; Aglietta, M.; Antonuzzo, L.; Aprile, G.; Berardi, R.; Cardellino, G.G.; De Manzoni, G.; De Vita, F.; et al. Trellemissumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-CoHort, Phase II INFINITY Study. *Cancers* 2021, 13, 2839. [CrossRef]

106. Park, J.; Shin, S.; Yoo, H.M.; Lee, S.W.; Kim, J.G. Evaluation of the Three Customized MSI Panels to Improve the Detection of Mi-crosatellite Instability in Gastric Cancer. *Clin Lab.* 2020, 66, 705–716. [CrossRef] [PubMed]

107. Périaux, A.; Favre, L.; Calderaro, J.; Charpy, C.; Derman, J.; Pujals, A. Detection of microsatellite instability in a panel of solid tu-mours with the Idylla MSI Test using extracted DNA. *J. Clin Pathol.* 2021, 74, 36–42. [CrossRef]

108. Farmkiss, L.; Hopkins, I.; Jones, M. Idylla microsatellite instability assay versus mismatch repair immunohistochemistry: A retro-spective comparison in gastric adenocarcinoma. *J. Clin Pathol.* 2021, 74, 604–607. [CrossRef] [PubMed]

109. Aysal, A.; Karnezis, A.; Medhi, I.; Grenert, J.P.; Zaloudek, C.J.; Rabban, J.T. Ovarian endometrioid adenocarcinoma: Incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor mi-crosatellite instability. *Am. J. Surg. Pathol.* 2012, 36, 163–172. [CrossRef] [PubMed]

110. Jensen, K.C.; Mariappan, M.R.; Putcha, G.V.; Husain, A.; Chun, N.; Ford, J.M.; Schrijver, I.; Longacre, T.A. Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger. *Am. J. Surg. Pathol.* 2008, 32, 1029–1037. [CrossRef]

111. Murphy, M.A.; Wentzensen, N. Frequency of mismatch repair deficiency in ovarian cancer: A systematic review article This year 2012–1922. [CrossRef] [PubMed]

112. Howitt, B.E.; Strickland, K.C.; Sholl, L.M.; Rodrig, S.; Ritterhouse, L.L.; Chowdhury, D.; D’Andrea, A.D.; Matulonis, U.A.; Konstantinopolous, P.A. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tu-mor-infiltrating lymphocytes and PD-1/PD-L1 expression. *Oncoimmunology* 2017, 6, e1277308. [CrossRef] [PubMed]

113. Shilpa, V.; Bhagat, R.; Premalata, C.S.; Pallavi, V.R.; Krishnamoorthy, L. Microsatellite instability, promoter methylation and the protein expression of the DNA mismatch repair genes in epithelial ovarian cancer. *Genomics* 2014, 104, 257–263.

114. Hodan, R.; Kingham, K.; Cotter, K.; Folkins, A.K.; Kurian, A.W.; Ford, J.M.; Longacre, T. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. *Cancer Med.* 2020, 10, 1012–1017. [CrossRef]

115. Latham, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Middha, S.; Hechtman, J.; Zehir, A.; Dubard-Gault, M.; et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol.* 2019, 37, 286–295. [CrossRef]

116. Yamashita, H.; Nakayama, K.; Ishikawa, M.; Ishibashi, T.; Nakamura, K.; Sawada, K.; Yoshimura, Y.; Tatsumi, N.; Kurose, S.; Minamoto, T.; et al. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. *Int. J. Mol. Sci.* 2019, 20, 5129. [CrossRef]

117. Lee, J.-H.; Cragun, D.; Thompson, Z.; Coppola, M.; Nicosia, S.V.; Akbari, M.; Zhang, S.; McLaughlin, J.; Narod, S.; Schildkraut, J.; et al. Association Between IHC and MSI Testing to Identify Mismatch Repair–Deficient Patients with Ovarian Cancer. *Int. J. Mol. Sci.* 2014, 18, 229–235. [CrossRef]

118. Rosen, D.G.; Cai, K.Q.; Luthra, R.; Liu, J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. *Mod. Pathol.* 2006, 19, 1414–1420. [CrossRef]

119. Cai, K.Q.; Albarracin, C.; Rosen, D.; Zhong, R.; Zheng, W.; Luthra, R.; Broaddus, R.; Liu, J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. *Hum. Pathol.* 2004, 35, 552–559. [CrossRef]

120. Travaglino, A.; Raffone, A.; Gencarelli, A.; Mollo, A.; Guida, M.; Insabato, L.; Santoro, A.; Zannoni, G.F.; Zullo, F. TCGA Classification of Endometrial Cancer: The Place of Carcinosarcoma. *Pathol. Oncol. Res.* 2020, 26, 2067–2073. [CrossRef] [PubMed]

121. Bianco, B.; Barbosa, C.P.; Treska, C.; Laganà, A.S.; Montagna, E. Endometrial cancer: A genetic point of view. *Transl. Cancer Res.* 2020, 9, 7706–7715. [CrossRef] [PubMed]
168. Hu, Z.I.; Shia, J.; Stadler, Z.K.; Varghese, A.M.; Capanu, M.; Salo-Mullen, E.; Lowery, M.A.; Diaz, L.A., Jr.; Mandelker, D.; Yu, K.H.; et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin. Cancer Res. 2018, 24, 1326–1336. [CrossRef]

169. Möller, P.; Seppälä, T.T.; Bernstein, I.; Holinski-Feder, E.; Sala, P.; Gareth Evans, D.; Lindblom, A.; Macrae, F.; Blanco, I.; Sijmons, R.H.; et al. Cancer risk and survival in path/MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database. Gut 2018, 67, 1306–1316. [CrossRef]

170. Ahmad-Nielsen, S.A.; Nielsen, M.F.B.; Mortensen, M.B.; Detlefsen, S. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Pathol. Res. Pract. 2020, 216, 152985. [CrossRef]

171. Lupinacci, R.M.; Bachet, J.B.; André, T.; Duval, A.; Svrek, M. Pancreatic ductal adenocarcinoma harboring microsatellite instability/DNA mismatch repair deficiency. Towards personalized medicine. Surg. Oncol. 2019, 28, 121–127. [CrossRef] [PubMed]

172. Riazy, M.; Kalloger, S.E.; Sheffield, B.S.; Peixoto, R.D.; Li-Chang, H.H.; Scudamore, C.H.; Renouf, D.J.; Schaeffer, D.F. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Med. Pathol. 2015, 28, 1383–1389. [CrossRef]

173. Lloyd, J.M.; Katz, M.H.G.; Wang, H.; Cuddy, A.; You, Y.N. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients with Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017, 152, 1086–1088. [CrossRef] [PubMed]

174. Marabelle, A.; Le, D.T.; Asciento, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair Deficient Can-cer: Results from the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2020, 38, 1–10. [CrossRef]

175. Xu, B.; Fuchs, T.; Dogan, S.; Landa, I.; Katabi, N.; Fagin, J.A.; Tuttle, R.M.; Sherman, E.; Gill, A.J.; Ghossein, R. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid 2020, 30, 1505–1517. [CrossRef] [PubMed]

176. Wong, K.S.; Lorch, J.H.; Alexander, E.K.; Nehs, M.A.; Nowak, J.A.; Hornick, J.L.; Barletta, J.A. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid 2019, 29, 666–673. [CrossRef]

177. Qiao, P.; Tian, K.-S.; Han, L.-T.; Ma, B.; Shen, C.-K.; Zhao, R.-Y.; Zhang, Y.; Wei, W.-J.; Chen, X.-P. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. Endocrine 2022, 76, 660–670. [CrossRef]

178. D’Andréa, G.; Lassalle, S.; Guevara, N.; Mograbi, B.; Hofman, P. From biomarkers to therapeutic targets: The promise of PD-L1 in thyroid autoimmunity and cancer. Theranostics 2021, 11, 1310–1325. [CrossRef]

179. Rocha, M.L.; Schmid, K.W.; Czapiewski, P. The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma—systematic review and discussion of current therapeutic options. Contemp. Oncol. 2021, 25, 213–223. [CrossRef]

180. Ülgen, E.; Can, Ö.; Bilguvar, K.; Oklay, Y.; Akyerli, C.B.; Danyeli, A.E.; Yakıcıer, M.C.; Sezerman, O.U.; Pamir, M.N.; Özдумan, K. Whole exome sequencing-based analysis to identify DNA damage repair deficiency as a major contributor to gliomagenesis in adult diffuse gliomas. J. Neuurosurg. 2019, 132, 1435–1446. [CrossRef]

181. Akur, E.; Saygin, I.; Erclin, M.E. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent gliblastoma. Turk. J. Med. Sci. 2021, 51, 1800–1808.

182. Kroiss, M.M.; Vogt, T.M.M.; Landthaler, M.; Schlegel, J.L.; Barletta, J.A. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid 2019, 29, 666–673. [CrossRef]

183. Birindelli, S.; Tragni, G.; Bartoli, C.; Ranzani, G.N.; Rilke, F.; Pierotti, M.A.; Pilotti, S. Detection of microsatellite alterations in recurrent and nonrecurrent glioblastoma. Contemp. Oncol. 2018, 22, 74–76. [CrossRef]

184. Uribe, P.; Wistuba, I.I.; Gonzalez, S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am. J. Dermatopathol. 2009, 31, 354–363. [CrossRef]

185. Kubeccek, O.; Trojanova, P.; Molnarova, V.; Kopecky, J. Microsatellite instability as a predictive factor for immunotherapy in ma-lignant melanomas. Med. Hypotheses 2016, 93, 74–76. [CrossRef]

186. Gayhart, M.G.; Johnson, N.; Paul, A.; Quillin, J.M.; Hampton, L.J.; Idowu, M.O.; Smith, S.C. Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma. Am. J. Clin. Pathol. 2020, 154, 792–801. [CrossRef]

187. Lindner, A.K.; Schachtner, G.; Tuchliner, G.; Thurnher, M.; Untergasser, G.; Obrist, P.; Pipp, I.; Steinkohl, F.; Horninger, W.; Cugil, Z.; et al. Lynch Syndrome: Its Impact on Urothelial Carcinoma. Int. J. Mol. Sci. 2021, 22, 531. [CrossRef]

188. Fraune, C.; Simon, R.; Hube-Magg, C.; Makrypidi-Fraune, G.; Kähler, C.; Blasco, I.; Höflmayer, D.; Büscheck, F.; Düm, D.; Luebke, A.; et al. MMR deficiency in uterine carcinosarcoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urol. Oncol. Semin. Orig. Invest. 2020, 38, 488–495. [CrossRef]

189. Metcalfe, M.J.; Petros, F.G.; Rao, P.; Mork, M.E.; Xiao, L.; Broadus, R.R.; Matin, S.F. Universal Point of Care Testing for Lynch Syn-drome in Patients with Upper Tract Urothelial Carcinoma. J. Urol. 2018, 199, 60–65. [CrossRef]

190. Harper, H.L.; McKenzie, J.K.; Heald, B.; Stephenson, A.; Campbell, S.C.; Plesec, T.; Magi-Galluzzi, C. Upper tract urothelial carcino-mas: Frequency of association with mismatch repair protein loss and Lynch syndrome. Mod. Pathol. 2017, 30, 146–156. [CrossRef]
191. Urakami, S.; Inoshita, N.; Oka, S.; Miyama, Y.; Nomura, S.; Arai, M.; Sakaguchi, K.; Kurosawa, K.; Okaneya, T. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Int. J. Urol. 2017, 25, 151–156. [CrossRef] [PubMed]

192. Ju, J.; Mills, A.M.; Mahadevan, M.S.; Fan, J.; Culp, S.H.; Thomas, M.H.; Cathro, H.P. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. Am. J. Surg. Pathol. 2018, 42, 1549–1555. [CrossRef] [PubMed]

193. Guedes, L.B.; Antonarakis, E.S.; Schweizer, M.T.; Mirkheshti, N.; Almutairi, F.; Park, J.C.; Glavaris, S.; Hicks, J.; Eisenberger, M.A.; De Marzo, A.M.; et al. MSH2 Loss in Primary Prostate Cancer. Clin. Cancer Res. 2017, 23, 6863–6874. [CrossRef] [PubMed]

194. Sedhom, R.; Antonarakis, E.S. Clinical implications of mismatch repair deficiency in prostate cancer. Futur. Oncol. 2019, 15, 2395–2411. [CrossRef] [PubMed]

195. Mollica, V.; Marchetti, A.; Rosellini, M.; Nuvola, G.; Rizzo, A.; Santoni, M.; Cimadamore, A.; Montironi, R.; Massari, F. An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. Int. J. Mol. Sci. 2021, 22, 13519. [CrossRef]